New Video Release: Electronic Consent (eConsent) for Remote Clinical Trials
Learn more about PharmaLedger’s solution for Electronic Consent for remote clinical trials.
PharmaLedger has just released a new explainer video covering our electronic Consent (eConsent) Use Case which aims to use blockchain technology to improve the informed consent process in clinical trials.
In order for a clinical trial to progress, any changes, risks or protocols must be communicated and confirmed by the patient participating. This process is known as “informed consent.” Find out more about the informed consent process and how PharmaLedger is initiating blockchain-enabled solutions in the new eConsent video, or read the brief summary below.
Current Challenges in Clinical Trials
Specific regulations regarding informed consent are applied in clinical trial processes in order to ensure quality, accuracy, integrity and regulatory data compliance. The current trial processes lack a trusted unified platform, which makes it difficult to have a seamless experience for those involved, both trial conductors and patients alike. Due to a lack of transparency and siloed information, many inefficiencies exist in the clinical trial ecosystem.
How PharmaLedger’s eConsent Use Case Works
PharmaLedger’s eConsent use case would allow for a transparent blockchain-based platform that can connect all stakeholders in the clinical trial ecosystem. The data captured on the blockchain would automatically be obliged to follow the instilled compliance rules set forth through permissioned remote site monitoring, and patients would be able to provide consent. Digitising and streamlining the entire clinical trial process would provide many benefits and improve the patient’s overall experience.
Thanks to blockchain, all of the processes and real-time data storage would improve traceability and allow for outer trial management. If a change in the trial occurs, a patient could quickly be informed of what they should or shouldn’t do, improving patient care and the efficiency of the process.
The trial also would adhere to blockchain-based smart contracts, which would allow patients to better control and manage who can access their personal data, in turn improving transparency, privacy and patient confidentiality.
How eConsent Would Benefit the Clinical Trial Ecosystem
The improvement of data accuracy and compliance through the use of blockchain can increase data quality and integrity. Automation of processes such as remote site monitoring can reduce time and cost to market.
Increased confidence in reducing the risk of non-compliance would result since there would be less document duplication and data transcriptions in clinics. Distributed Ledger Technologies could allow remote visits and the ability to prioritise urgent treatments in hospitals by easing the patient load
A new level of empowerment, control, participation and accessibility thanks to the new features made possible with blockchain. This would include choosing and having full insight as to who can access their private data and how it’s being used.
Additionally, PharmaLedger’s eConsent use case overlaps with our other use cases, such as remote monitoring through the Internet of Things (IoT) and Personalised Medicine use cases. You can look forward to additional explainer videos about these use cases in the near future, which you’ll find on our Youtube channel.
Sign up for our monthly newsletter below to get the latest PharmaLedger news to your inbox.